156. レット症候群 ［臨床試験数：36，薬物数：49（DrugBank：19），標的遺伝子数：77，標的パスウェイ数：112］
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||EUCTR2019-001605-24-GB||15/01/2020||23/10/2019||An open label extension study for long-term safety of GWP42003-P in patients with Rett Syndrome||An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome||Rett syndrome (RTT) [typical or atypical] |
MedDRA version: 20.0Level: PTClassification code 10077709Term: Rett syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|Trade Name: CBD Oral solution, is known as Epidyolex and is the approved name in the EU|
Product Name: Cannabidiol (CBD)
Product Code: GWP42003-P
INN or Proposed INN: Cannabidiol
Other descriptive name: CANNABIDIOL
|GW Research Ltd||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|252||Phase 3||United States;France;Canada;Spain;Australia;Italy;United Kingdom|